Available to SourceHuman Prescription DrugOncology & Specialty

Epclusa (Velpatasvir and Sofosbuvir)

200 mg/1 / 50 mg/1 · Pellet

By Gilead Sciences, Inc.

Velpatasvir and Sofosbuvir · Pellet · 200 mg / 50 mg

NDC: 61958-2204
Route: Oral
Therapeutic class: Breast Cancer Resistance Protein Inhibitors [MoA], Hepatitis C Virus NS5A Inhibitor , Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor , Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], RNA Replicase Inhibitors [MoA]
Marketing category: NDA

Request This Medication

*Expect a reply within 2 business hours with availability and pricing.

Additional information

Full prescribing information for this product is available on request. Submit a sourcing request and our team will share lot details, dating, and current pricing.

Request a quote

Request this medication.

Pick the package size you need and we’ll respond with availability, lot details, dating, and pricing within 2 business hours. Mark it as Rush or Emergency if you need it faster.

DSCSA-compliant pedigree on every order
Cold-chain capable where applicable
Same-day fulfillment available for urgent needs

Related in Oncology & Specialty

See all →

Epclusa (Velpatasvir and Sofosbuvir)

Additional information

Request this medication.

Related in Oncology & Specialty

Verzenio (Abemaciclib)

Verzenio (Abemaciclib)

Verzenio (Abemaciclib)

Verzenio (Abemaciclib)